Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093951 · ClinicalTrials.gov registry record · Phase 2
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study of Alzheimers Disease, sponsored by Saegis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT00093951: Completed Phase 2 study of Alzheimers Disease, sponsored by Saegis Pharmaceuticals.
NCT00093951 is a Phase 2 study of Alzheimers Disease that has completed, run by Saegis Pharmaceuticals. The registered enrollment target is 280 participants, below the 3,924-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093951, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Saegis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
Conditions Studied
Interventions
- DRUG SGS742
Study Locations (20)
California
- Margolin Brain Institute - Fresno
- NervePro Research - Irvine
- Center for Neurologic Studies - La Jolla
- Neuro Therapeutics, Inc. - Pasadena
- Pacific Research Network, Inc. - San Diego
- Affiliated Research Institute - San Diego
- San Francisco Clinical Research Center - San Francisco
- Southern California Clinical Research, Inc. - San Marino
Florida
- Baumel-Eisner Neuromedical Institute, Inc. - Boca Raton
- Bradenton Neurology, Inc. - Bradenton
- Brain Matters, Inc. - Delray Beach
- Baumel-Eisner Neuromedical Institute - Fort Lauderdale
- Berma Research Group - Hialeah
Arizona
- - Phoenix
- Dedicated Clinical Research - Sun City
- Northwest NeuroSpecialists, PLLC - Tucson
Connecticut
- Research Center for Clinical Studies, Inc. - Darien
- - Stamford
Arkansas
- Clinical Trials Incorporated - Little Rock
Colorado
- The Mile High Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00093951 record still lists
NCT00093951 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 3,924-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which SGS742 is the first listed.
NCT00093951 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00093951 about?
NCT00093951 is a clinical study titled "SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)". The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
What is the current status of trial NCT00093951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2004-04. Estimated completion is 2007-09.
What conditions does trial NCT00093951 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00093951?
The interventions under investigation include: SGS742 (DRUG).
Who is sponsoring clinical trial NCT00093951?
This trial is sponsored by Saegis Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00093951 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00093951's enrollment target sits among peer trials
280 42nd of 147 higher than 104 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia